SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cheifetz A, Mayer L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mount Sinai J Med 72(4):250256.
  • 2
    Pendley C, Schantz A, Wagner C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5(2):172179.
  • 3
    Porter S. 2001. Human immune response to recombinant human proteins. J Pharm Sci 90(1):111.
  • 4
    Koren E, Zuckerman LA, Mire-Sluis A. 2002. Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr Pharm Biotechnol 3:349360.
  • 5
    Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I. 2007. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7(3):405418.
  • 6
    Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24(11):17201740.
  • 7
    Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20(Suppl. 6):vi3vi9.
  • 8
    Schellekens H. 2008. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191202.
  • 9
    Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development Dev Biol 112:8197.
  • 10
    Barbosa MDFS, Celis E. 2007. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today 12(15–16):674681.
  • 11
    Chirino AJ, Ary ML, Marshall SA. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9(2):8290.
  • 12
    De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482490.
  • 13
    Herzyk D. 2003. The Immunogenicity of therapeutic cytokines. Curr Opin Mol Ther 5(2):167171.
  • 14
    Ponce R, Abad L, Amarvadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. 2009. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54:164182.
  • 15
    Presta LG. 2006. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640656.
  • 16
    Ryff J-C, Schellekens H. 2002. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 23(6):254256.
  • 17
    Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21(6):897903.
  • 18
    Rosenberg AS. 2006. Effect of protein aggregates: An immunologic perspective. AAPS J 8(3):E501E507.
  • 19
    Cordoba-Rodriguez RV. 2008. Aggregates in MAbs and recombinant therapeutic proteins: A regulatory perspective. BioPharm Int 21(11):4453.
  • 20
    Sharma B. 2007. Immunogenicity of therapeutic proteins, Part I: Impact of product handling. Biotechnol Adv 25:310317.
  • 21
    Sharma B. 2007. Immunogenicity of therapeutic proteins, Part 2: Impact of container closures. Biotechnol Adv 25:318324.
  • 22
    Sharma B. 2007. Immunogenicity of therapeutic proteins, Part 3: Impact of manufacturing changes. Biotechnol Adv 25:325331.
  • 23
    Clark M. 2000. Antibody humanization: A case of the emperor's new clothes? Immunol Today 21(8):397402.
  • 24
    Cohen BA, Oger J, Gagnon A, Giovannoni G. 2008. The implication of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 275:717.
  • 25
    Delves PJ, Roitt IM. 2000. The immune system, Part I. New Engl J Med 343(1):3749.
  • 26
    Delves PJ, Roitt IM. 2000. The immune system, Part II. New Engl J Med 343(2):108117.
  • 27
    Mukovozov I, Sabljic T, Hortelano G, Ofosu FA. 2007. Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. Thromb Haemost 99:874882.
  • 28
    Parkin J, Cohen B. 2001. An overview of the immune system. Lancet 357:17771789.
  • 29
    Debenedictis C, Joubeh S, Zhang G, Barria M, Ghohestani RF. 2001. Immune functions of the skin. Clin Dermatol 19:573585.
  • 30
    Baker MP, Jones, TD. 2007. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Dev 10(2):219227.
  • 31
    Balazs M, Martin F, Zhou T, Kearney JF. 2002. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17:341352.
  • 32
    Vos Q, Lees A, Wu Z-Q, Snapper CM, Mond JJ. 2000. B-cell activation by T-cell-independent Type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms Immunol Rev 176:154170.
  • 33
    Batista FD, Harwood, NE. 2009. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9(1):1527.
  • 34
    Prieto A, Villaneuva A, Lain S, Baeza ML. 2008. Fatal intraoperative anaphylaxis after aprotinin administration. J Invest Allergol Clin Immunol 18(2):136.
  • 35
    Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part I: Considering consequences of the immune response to a protein. BioPharm Int 17(11):2226.
  • 36
    Kropshofer H, Schellekens H. 2009. Impact of the formulation on the immunogenicity of protein drugs. In Protein pharmaceuticals—formulation, analytics and delivery; MahlerH-C, LuessenH, BorchardG, Eds. Aulendorf, Germany: Editio Cantor Verlag, pp. 294309.
  • 37
    Sauerborn M, Brinks V, Jiskoot W, Schellekens H. 2009. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):5359.
  • 38
    Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part II: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int 17(12):3442.
  • 39
    Descates J. 2009. Immunotoxicity of monoclonal antibodies. mAbs 1(2):104111.
  • 40
    Tabrizi MA, Roskos LK. 2007. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 12(13–14):540547.
  • 41
    Barbosa MDFS, Vielmetter J, Chu S, Smith DD, Jacinto J. 2006. Clinical link between MHC Class II haplotype and interferon-beta (IFN-β) immunogenicity. Clin Immunol 118:4250.
  • 42
    Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S. 2009. The association of anti-r-HuEPO-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant 24:15451549.
  • 43
    van Regenmortel MHV, Boven K, Bader F. 2005. Immunogenicity of biopharmaceuticals: An example from erythropoietin. BioPharm Int 18(8):3652.
  • 44
    Perini P, Facchinetti A, Bulian P, Massaro AR, De Pascalis D, Bertolotto A, Biasi G, Gallo P. 2001. Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 12(1):5661.
  • 45
    Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. 2009. Effect of route of administration of human recombinant Factor VIII on its immunogenicityin Hemophilia A mice. J Pharm Sci 98(12):44804484.
  • 46
    Adalimumab. 2002. Pharmacology Reviews: Adalimumab product approval information—licensing action 12/31/02. Rockville, MD: Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm. Accessed March 2009.
  • 47
    Fineberg SE. 2006. Diabetes therapy trials with inhaled insulin. Expert Opin Invest Drugs 15(7):743762.
  • 48
    Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. 2004. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. A 12-week proof-of-concept trial in patients with Type 2 diabetes. Diabetes Care 27(1):162167.
  • 49
    Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. 2005. Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. an analysis of initial phase ii and iii inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocr Metab 90:32873294.
  • 50
    Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. 1997. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells. Cytokines Cell Mol Ther 3:2732.
  • 51
    Antonelli G, Dianzini F. 1999. Development of Antibodies to interferon beta in patients: Technical and biological aspects. Eur Cytokine Netw 10(3):413422.
  • 52
    Anderson PJ. 2005. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(Suppl. 1):1922.
  • 53
    Jahn E-M, Schneider C. 2009. How to systematically evaluate immunogenicity of therapeutic proteins—regulatory considerations. New Biotechnol 25(5):280286.
  • 54
    Rup B. 2003. Immunogenicity and immune tolerance coagulation factors VIII and IX. Dev Biol 112:5559.
  • 55
    De Groot AS, McMurry J, Moise L. 2008. Prediction of immunogenicity: In silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620626.
  • 56
    Dillon T, Bondarenko P, Wypych J, Allen M, Balland A, Ricci MS, Guo A, Shen W, Sun J, Vezina C, Hwang I, Park S. 2008. Computational design of protein therapeutics. Drug Discov Today Technol 5(2–3):e43e48.
  • 58
    Wang X, Das TK, Singh SK, Kumar S. 2009. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. mAbs 1(3):254267.
  • 59
    Cromwell MEM, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3):E572E579.
  • 60
    Chen B, Bautista R, Yu K, Zapata GA, Mukerrin MG, Chamow SM. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms Pharm Res 20(12):19521960.
  • 61
    Lam XM, Yang JY, Cleland JM. 1997. Antioxidants for the prevention of methionine oxidation in recombinant monoclonal antibody Her2 J Pharm Sci 86(11):12501255.
  • 62
    Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98(9):32183238.
  • 63
    Bhatnagar B, Bogner RH, Pikal MJ. 2007. Protein stability during freezing: Separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12:505523.
  • 64
    Singh SK, Kolhe P, Wang W, Nema S. 2009. Large-scale freezing of biologics—a practitioner's review, Part I: Fundamental aspects. BioProcess Int 7(10):3244.
  • 65
    Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98(1):94104.
  • 66
    Jones LS, Kaufman A, Middaugh CR. 2005. Silicone oil induced aggregation of proteins. J Pharm Sci 94(4):918927.
  • 67
    Bee JS, Nelson SA, Freund E, Carpenter JF, Randolph TW. 2009. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 98(9):32903301.
  • 68
    Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6(11):903918.
  • 69
    Kiese S, Pappenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred—mechanical stress testing of an IgG1 antibody. J Pharm Sci 97(10):43474366.
  • 70
    Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19(4):511516.
  • 71
    Fakharzadeh SS, Kazazian HH. 2000. Correlation between Factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26(2):167171.
  • 72
    Richards SM. 2002. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev 2:241253.
  • 73
    Diamond B. 2003. Speculations on the immunogenicity of self proteins. Dev Biol 112:2934.
  • 74
    Ottensen JL, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D, Havelund S, Fogh JM. 1994. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:11781185.
  • 75
    Schnabel CA, Fineberg SE, Kim DD. 2006. Immunogenicity of xenopeptide hormone therapies. Peptides 27:19021910.
  • 76
    Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. 2007. Immunological responses to exogeneous insulin. Endocr Rev 28(6):625652.
  • 77
    Kaplan SL, August GP, Blethen SL, Hintz RL, Johansen A, Plotnick LP, Underwood LE, Bell JJ, Blizzard RM, Foley TP, Hopwood NJ, Kirkland RT, Rosenfeld RG, Van Wyk JJ. 1986. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 327(8483):697700.
  • 78
    Massa G, Vanderschueren-Lodeweyckx M, Bouillion R. 1993. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol 38:137142.
  • 79
    Aston R, Cooper L, Holder A, Ivanyi J, Freece M. 1985. Monoclonal antibodies to human growth hormone can distinguish between pituitary and genetically engineered forms. Mol Immunol 22(3):271275.
  • 80
    Rougeot C, Marchand P, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R. 1991. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 35:7681.
  • 81
    Valls C, Pavia C, Rivera F, Mauri M, Sampere JJM, Fernandez JJ, Colon C, Pombo M, Perez de Mezquia C, Sobradillo B, Carralero I. 1993. Treatment with growth hormone. A comparative study of the antigenicity of different commercial preparations. Serono Symp Publ 100(TWO):113.
  • 82
    Robbins DC, Cooper SM, Fineberg SE, Mead PM. 1987. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838841.
  • 83
    Ratner RE, Phillips TM, Steiner M. 1990. Persistent cutaneous insulin allergy resulting from high-molecular weight insulin aggregates. Diabetes 39:728733.
  • 84
    Dipaola M, Smith T, Ferencz-Biro K, Liao M-J, Testa D. 1994. Interferon-α2 produced by normal human leukocytes is predominantly interferon-α2b. J Interferon Res 14:325332.
  • 85
    Pestka S. 2007. The interferons: 50 years after their discovery, there is much to learn. J Biol Chem 282(28):2004720051.
  • 86
    Blatt LM, Davis JM, Klein SB, Taylor MW. 1996. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cyokine Res 16:489499.
  • 87
    Itri LM, Campion M, Dennin RA, Palleroni AV, Gutterman JU, Groopman JE, Trown PW. 1987. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 59:668674.
  • 88
    Von Wussow P, Hehlmann R, Hochhaus T, Jakschies D, Nolte KU, Prummr O, Ansari H, Hasford J, Heimpel H, Deicher H. 1994. Roferon (rIFN-α2a) is more immunogenic than intron A (rIFN-α2b) in patients with chronic myelogenous leukemia. J Interferon Res 14:217219.
  • 89
    Antonelli G, Currenti M, Turriziani O, Dianzini F. 1991. Neutralizing antibodies in interferon-α: Relative frequency in patients treated with different interferon preparations. J Infect Dis 163:882885.
  • 90
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, Consensus Interferon Study, Group1997. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology 26(3):747754.
  • 91
    Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Fruhbeis B, Lamche H, Lindner J, Patselt E, Schmahling C, Schneider F-J. 1992. Low incidence of antibody formation due to long-term interferon-α2c treatment of cancer patients. Clin Invest 70:136141.
  • 92
    Palleroni AV, Aglione A, Labow M, Brunda MJ, Pestka S, Sinigaglia F, Garotta G, Alsenz J, Braun A. 1997. Interferon immunogenicity: Preclinical evaluation of interferon-α2a. J Interferon Cyokine Res 17(Suppl. 1):S23S27.
  • 93
    Kontsek P, Liptakova H, Kontsekova E. 1999. Immunogenicity of interferon-alpha2 in therapy: Structural and physiological aspects. Acta Virol 43:6370.
  • 94
    Gabain AV, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan SS. 1990. Three human interferon-α2 subvariants disclose structural and functional differences. Eur J Biochem 190:257261.
  • 95
    Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res 15(4):641649.
  • 96
    Ross C, Clemmsen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgard GL, Bendtzen K. 2000. Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose, frequency, and route of administration. Ann Neurol 48:706712.
  • 97
    Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, Ruggieri M, Bruschi F, Meucci G, Dicounzo G, Antonelli G. 2002. Neutralizing and binding antibodies to IFN-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J Interferon Cyokine Res 22:207213.
  • 98
    Rudick RA, Simonain NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:12661272.
  • 99
    Bertolotto A, Deisenhammer F, Gallo P, Sorensen PS. 2004. Immunogenicity of interferon beta: Differences among products. J Neurol 251(Suppl. 2):II/15–II/24.
  • 100
    Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B. 2002. Randomized, comparative study of interferon β-1a treatment regimens in MS. The Evidence trial. Neurology 59:14961506.
  • 101
    Cook SD, Quinless JR, Jotkowitz A, Beaton P. 2001. Serum IFN neutralizing antibodies and neotropin levels in a cross-section of MS patients. Neurology 57:10801084.
  • 102
    Hwang WYK, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:310.
  • 103
    Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. 2008. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 20:493499.
  • 104
    Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster F-P, Heilig B. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269274.
  • 105
    Abbot. 2002. Humira (adalimumab). Full prescribing information from Abbot. Abbot Park, IL, USA. http://www.humira.com/. Accessed January 2009.
  • 106
    van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Sttas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508516.
  • 107
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. 2003. Adalimumab. A fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 48(1):3545.
  • 108
    Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson Jr JH. 2003. Effect of long-term exposure to Insulin Lispro on the induction of antibody response in patients with Type 1 or Type 2 diabetes. Diabetes Care 26(1):8996.
  • 109
    Sethuraman N, Stadheim TA. 2006. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17:341346.
  • 110
    Shantha Raju T. 2003. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProcess Int 1(4):4453.
  • 111
    Sheeley DM, Merrill BM, Taylor LCE. 1997. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal α-linked galactose. Anal Biochem 247:102110.
  • 112
    Walsh G, Jefferis R. 2006. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10):12411252.
  • 113
    Yeun C-T, Storring PL, Tiplady RJ, Izquierdo M, Wait R, Gee CK, Gwerson P, Lloyd P, Cremata JA. 2003. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haemotol 121:511526.
  • 114
    Werner RG, Noe W, Kopp K, Schluter M. 1998. Appropriate mammalian expression systems for biopharmaceuticals. Arzneim-Forsch/Drug Res 48(8):870880.
  • 115
    Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226234.
  • 116
    Devasahayam M. 2007. Factors affecting the expression of recombinant glycoproteins. Indian J Med Res 126:2227.
  • 117
    Wright A, Morrison SL. 1997. Effect of glycosylation on antibody function: Implication for genetic engineering. Trends Biotechnol 15:2632.
  • 118
    Ashford DA, Alafi CD, Gamble VM, Mackay DJG, Rademacher TW, Williams PJ, Dwek RA, Niel Barclay A, Davis SJ, Somoza C, Ward HA, Williams AF. 1993. Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in Chinese hamster ovary cells. J Biol Chem 268(5):32603267.
  • 119
    Galili U, Macher BA, Buehler J, Shohet SB. 1985. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1–3)-linked galactose residues J Exp Med 162:573582.
  • 120
    Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadropole–quadropole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364:818.
  • 121
    Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 358(11):11091117.
  • 122
    Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. 2000. Exposure to topical bovine thrombin during surgery elicits a response against the xenogenic carbohydrate galactose alpha1–3galactose J Clin Immunol 20:434444.
  • 123
    Lawson JH. 2006. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 32(Suppl. 1):98110.
  • 124
    Chenu S, Gregoire A, Malykh Y, Visvikis A, Monaco L, Shaw L, Schauer R, Marc A, Goergen J-L. 2003. Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy. Biochim Biophys Acta 1622:133144.
  • 125
    Brooks SA. 2006. Protein glycosylation in diverse cell systems: Implication for modification and analysis of recombinant proteins. Expert Rev Proteomics 3(3):345359.
  • 126
    Gerngross TU. 2004. Advances in the Production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22(11):14091414.
  • 127
    Wildt S, Gerngross TU. 2005. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 3:119128.
  • 128
    Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21:1116.
  • 129
    Lis H, Sharon N. 1993. Protein glycosylation. Structural and functional aspects. Eur J Biochem 218:127.
  • 130
    Sinclair AM, Elliott S. 2005. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94(8):16261635.
  • 131
    Spiro RG. 2002. Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12(4):43R-56R.
  • 132
    Schirrmann T, Al-Halabi L, Dubel S, Hust M. 2008. Production system for recombinant antibodies. Front Biosci 13(May):45764594.
  • 133
    Sola RJ, Griebenow K. 2009. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98(4):12231245.
  • 134
    Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 37:697706.
  • 135
    Ho C-L, Lin Y-L, Chen W-C, Rocchi R, Piek T. 1998. Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties. Toxicon 36(1):217221.
  • 136
    Kosloski MP, Miclea RD, Balu-Iyer SV. 2009. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human Factor VIII. The AAPS Journal, 11(3), 424431.
  • 137
    Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch DC. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434437.
  • 138
    McNeel DG, Schiffman K, Disis ML. 1999. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93(8):26532659.
  • 139
    Ullenhag G, Bird C, Ragnhammar P, Frodin JE, Strigard K, Osterborg A, Thorpe R, Mellstedt H, Wadhwa M. 2001. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol 99(1):6574.
  • 140
    Conradt HS, Geyer R, Hoppe J, Grotjahn L, Plessing A, Mohr H. 1985. Structures of the major carbohydrates of natural human interleukin-2. Eur J Biochem 153:255261.
  • 141
    Bergmann CA, Landmeier BJ, Kaplan DR. 1991. Phase separation analysis of recombinant interleukin 2. Mol Immunol 28(1–2):99105.
  • 142
    Prummer O. 1997. Treatment induced antibodies to interleukin-2. Biotherapy 10:1524.
  • 143
    Mack G. 2008. FDA balks at myozyme scale-up. Nat Biotechnol 26(6):592.
  • 144
    Yao L. 2008. Myozyme: FDA Advisory Committee briefing document. Alglucosidase alfa 2000 L for late-onset Pompe disease. Clinical Background Materialshttp://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4389b1-01-FDA.pdf.. Accessed March 2009.
  • 145
    Abuchowski A, van Es T, Palczuk NC, Davis FF. 1977. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252(11):35783581.
  • 146
    Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. 1977. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252(11):35823586.
  • 147
    Chapman AP. 2002. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 54:531545.
  • 148
    Katre NV. 1990. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 144(1):209213.
  • 149
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh M-C, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. 2006. Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17:618630.
  • 150
    Edwards III CK, Martin SSW, Seely J, Kinstler O, Buckel S, Bendele AM, Cosenza ME, Feige U, Kohno T. 2003. Design of PEGylated soluble tumor necrosis factor receptor Type 1 (PEG sTNF-R1) for chronic inflammatory diseases. Adv Drug Deliv Rev 55:13151326.
  • 151
    Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA. 1991. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci U S A 88:71857189.
  • 152
    Avamis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS. 2002. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group Study. Blood 99(6):19861994.
  • 153
    Graham ML. 2003. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 55:12931302.
  • 154
    Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. 1992. IgG Antibody response to polyethylene glycol—modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89:16431651.
  • 155
    Bukowski RM, Young J, Goodman G, Meyers F, Issell BF, Sergi JS, McLain D, Fyfe G, Finke J. 1993. Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs 11:211217.
  • 156
    Li J, Yang C, Xia Y, Bertina A, Glaspy J, Roberts M, Kuter DJ. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12):32413248.
  • 157
    Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS. 2002. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99(6):19861994.
  • 158
    Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:12611277.
  • 159
    Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. 2006. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase 1 trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8:R12.
  • 160
    Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. 2007. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110:103111.
  • 161
    Bendele A, Seely J, Richey C, Sennello G, Shopp G. 1998. Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42:152157.
  • 162
    Fernandes AI, Gregoriadis G. 2001. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics. Int J Pharm 217:215224.
  • 163
  • 164
    Lundin K, Berger L, Blomberg F, Wilton P. 1991. Development of anti-hGH antibodies during therapy with authentic human growth hormone. Acta Paediatr Scand 372(Suppl.):167168.
  • 165
    Wadhwa M, Skog A-LH, Bird C, Ragnhammar P, Lilljefors M, Gaines-Das R, Mellstedt H, Thorpe R. 1999. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 5:13531361.
  • 166
    Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709760.
  • 167
    Novo Nordisk. 2008. NovoSevenRT (rFactorVIIa). Full prescribing information from Novo Nordisk. Princeton, NJ, USA. http://www.novosevenrt.com/. Accessed February 2009.
  • 168
    Balint Jr JP, Jones FR. 1995. Evidence for proteolytic cleavage of covalently bound Protein A from a silica based extracorporeal immunoadsorbent and lack of relationship to treatment effects. Transfus Sci 16(1):8594.
  • 169
    European Medicines Agency. 2006. Omnitrope (rhSomatropin). EPAR Scientific Discussion. London: European Medicines Agency. http://www.ema.europa.eu/htms/human/epar/eparintro.htm. Accessed December 2008
  • 170
    European Medicines Agency. 2006. Myozyme(Alglucosidase-α). EPAR Scientific Discussion. London: European Medicines Agency. http://www.ema.europa.eu/htms/human/epar/eparintro.htm. Accessed January 2009
  • 171
    Anderton SM. 2004. Post-translational modifications of self-antigens: Implications for autoimmunity. Curr Opin Immunol 2004(16):753758.
  • 172
    Doyle H, Mamula MJ. 2001. post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 22(8):443449.
  • 173
    Kasama T, Iwata Y, Oshiro K, Uchida M, Sakaguchi Y, Namie K, Sugiura M. 1981. Antigenicity of desamido-insulin and monocomponent insulin. Diabetologia 21:6569.
  • 174
    Chen W, Ede NJ, Jackson DC, McCluskey J, Purcell AW. 1996. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J Immunol 157:10001005.
  • 175
    Mowat AM. 2003. Coeliac disease—a meeting point for genetics, immunology, and protein chemistry. Lancet 361:12901292.
  • 176
    Weintraub SJ, Manson SR. 2004. Asparagine deamidation: A regulatory hourglass. Mech Aging Dev 125:255257.
  • 177
    Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. 2005. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77:14321439.
  • 178
    Rutault K, Alderman C, Chain BM, Katz DR. 1999. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic Biol Med 26(1–2):232238.
  • 179
    Gallucci S, Matzinger P. 2001. Danger signals: SOS to the immune system. Curr Opin Immunol 13:114119.
  • 180
    Carrasco-Marin E, Paz-Miguel JE, Lopez-Mato P, Alvarez-Dominguez C, Lefya-Cobain F. 1998. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T-cells. Immunology 95:314321.
  • 181
    Rasheed Z, Ali R. 2006. Reactive oxygen species damaged human serum albumin in patients with Type I diabetes mellitus: Biochemical and immunological studies. Life Sci 79:23202328.
  • 182
    Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M. 2001. Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 18(5):632639.
  • 183
    Gitlin G, Tsarbopoulos A, Patel ST, Sydor W, Pramanik BN, Jacobs S, Westreich L, Mittelman S, Bausch JN. 1996. Isolation and characterization of a monomethioninesulfoxide variant of interferon α-2b. Pharm Res 13(5):762769.
  • 184
    Hochuli E. 1997. Interferon immunogenicity: Technical evaluation of interferon-α2a. J Interferon Cyokine Res 17(Suppl. 1):S15S21.
  • 185
    Nilsson MR, Driscoll M, Raliegh DP. 2002. Low levels of asparagine deamidation can have a dramatic effect upon aggregation of amyloidogenic proteins: Implications for the study of amyloid proteins. Prot Sci 11:342349.
  • 186
    Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solutions: Mechanisms and driving forces in non-native protein aggregation. Pharm Res 20(9):13251336.
  • 187
    Wang W. 2005. Protein aggregation and its inhibition in biopharmaceuticals Int J Pharm 289:130.
  • 188
    Mahler H-C, Freiss W, Grauschopf U, Keise S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):29092934.
  • 189
    Medzhitov R, Janeway Jr CA. 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296:298300.
  • 190
    Dintzis HM, Dintzis RZ, Vogelstein B. 1976. Molecular determinants of immunogenicity—immunon model of immune response. Proc Natl Acad Sci U S A 73:36713675.
  • 191
    Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. 1993. The influence of antigen organization on B cell responsiveness. Science 262:14481451.
  • 192
    Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. 2006. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40:19.
  • 193
    Babuik S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, Babuik L. 2004. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: Evidence from a mouse model. J Med Virol 72:138142.
  • 194
    Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98(9):32473264.
  • 195
    White PJ, Anastasopoulos F, Church JE, Kuo C-Y, Boyd BJ, Hickey PLC, Sze Tu L, Burns P, Lew AM, Heath WR, Davey GM, Pouton CW. 2008. Generic construction of single-component particles that elicit humoral and cellular responses without the need for adjuvants. Vaccine 26:68246831.
  • 196
    Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol 51(4):691697.
  • 197
    Ahangari G, Ostadali MR, Rabani A, Rashidian J, Sanati MH, Zarindast MR. 2004. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. Int J Immunopathol Pharmacol 17(1):3338.
  • 198
    Baumann G, Winter RJ, Shaw M. 1987. Circulating molecular variants of growth hormone in childhood. Pediatr Res 22(1):2122.
  • 199
    Stolar MW, Amburn K, Baumann G. 1984. Plasma “big” and “big-big” growth hormone (GH) in man: An oligomeric series composed of structurally diverse GH monomers. J Clin Endocrinol 59(2):212218.
  • 200
    Jeandidier N, Boullu S, Busch-Brafin M-S, Chabrier G, Sapin R, Gasser F, Pinget M. 2002. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in Type I diabetic patients. Diabetes Care 25(1):8488.
  • 201
    Jeandidier N, Boullu S, Delatte E, Sapin R, Steibel J, Meyer P, Uhl C, Pinget M. 2001. High antigenicity of intraperitoneal insulin infusion via implantable devices: Preliminary rat studies. Horm Metab Res 33:3438.
  • 202
    Pinget M, Jeandidier N. 1998. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Horm Metab Res 30:475486.
  • 203
    Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. 1997. Toward understanding insulin fibrillation. J Pharm Sci 86(5):517525.
  • 204
    Ryff J-C. 1997. Clinical Investigation of the immunogenicity of interferon-α2a. J Interferon Cyokine Res 17(Suppl. 1):S29S33.
  • 205
    Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm Res 14(10):14721478.
  • 206
    Hermeling S, Aranha L, Damen JMA, Slijper M, Schellekens H, Crommelin DJA, Jiskoot W. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22(12):19972006.
  • 207
    Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MFBG. 2007. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 282(4):22292236.
  • 208
    Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95(2):358371.
  • 209
    Gribble EJ, Sivakumar PV, Ponce RA, Hughes SD. 2007. Toxicity as a result of immunostimulation by biologics. Expert Opin Drug Metab Toxicol 3(2):209234.
  • 210
    Fleischmann JD, Wentworth D, Valencic F, Imbembo AL, Koehler KA. 1988. Interleukin-2 self-association. Biochem Biophys Res Commun 152(2):879885.
  • 211
    Novartis. 2007. Proleukin (aldesleukin). Full prescribing information by Novartis. East Hanover, NJ, USA. http://www.proleukin.com/. Accessed February 2009
  • 212
    Geigert J, Solli N, Woehleke P, Vemuri S. 1993. Development and shelf-life determination of recombinant interleukin-2 (Proleukin). In Stability and characterization of protein and peptide drugs: Case histories; WangJY, PearlmanR, Eds. New York: Plenum Press, p 249262.
  • 213
    Arakawa T, Boone T, Davis JM, Kenney WC. 1986. Structure of unfolded and refolded recombinant derived [Ala125]interleukin-2. Biochemistry 25:82748277.
  • 214
    Curatolo L, Valasina B, Caccia C, Raimondi GL, Orsini G, Bianchetti A. 1997. Recombinant human IL-2 is cytotoxic to oligodendrocytes after in vitro self aggregation. Cytokine 9(10):734739.
  • 215
    Kaplan DR. 1994. Delivery of interleukin 2 for immunotherapy. J Chromatogr B 662:315323.
  • 216
    Kunitani M, Hirtzer P, Johnson D, Halenbeck R, Boosman A, Koths K. 1986. Reversed-phase chromatography of interleukin-2 muteins. J Chromatogr 359:391402.
  • 217
    Denis MC, Huner BT. 2003. Native and recombinant interleukin-2, two functionally distinct molecules. Mol Immunol 40:279286.
  • 218
    Knuver-Hopf J, Mohr H. 1995. Differences between natural and recombinant interleukin-2 revealed by gel electrophoresis and capillary electrophoresis. J Chromatogr A 717:7174.
  • 219
    Shaker MA, Younnes HM. 2009. Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 98(7):22682298.
  • 220
    Belloni F, Muto A, Palmieri G, Focaccetti C, Dianzini C, Mattei M, Jaber A, Antonelli G. 2007. Immunogenicity comparison of interferon beta-1a preparations using BALB/c mouse model: Assessment of a new formulation for use in multiple sclerosis. New Microbiol 30():241246.
  • 221
    Brearley C, Jaber A, Bertolino M, Priestley A, Seiberling M. 2007. Assessment of the safety, tolerability, and PK/PD properties of two new formulation of subcutaneously administered IFN-β1a: A double-blind placebo-controlled comparison with the currently available formulation. Int J Clin Pharmacol Ther 45(6):307318.
  • 222
    Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M. 2007. The Rebif new formulation story. It's not trials and error. Drugs R&D 8(6):335348.
  • 223
    Jaber A, Baker M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharmacol Biomed Anal 43:12561271.
  • 224
    Giovannoni G, Barbarash O, casset-Semanez F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sorensen PS, Stubinski B. 2007. Immunogenicity and Tolerability of an Investigational Formulation of Interferon-β1a: 24- and 48-Week Interim Analyses of a 2-Year, Single-Arm, Historically Controlled Phase IIIb Study in Adults with Multiple Sclerosis. Clinical Therapeutics 29(6):11281145.
  • 225
    Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW, Briet E. 1993. A Sudden increase in Factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 81(8):21802186.
  • 226
    Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquermin M, Saint-Remy JMR, Vermylen J. 1997. Factor VIII inhibitors in previously treated haemophilia A Patients with a double virus-inactivated plasma derived Factor VIII concentrate. Thromb Haemost 77(1):8086.
  • 227
    Robinson S, Schwinn H, Josic D, Nur I, Stadler M, Bal F, Gehringer W, Schutz R. 1995. Development and biochemical characterization of double-virus inactivated Factor VIII preparation. Blood Coagul Fibrinolysis 6(Suppl. 2):S40S47.
  • 228
    Wang W, Kelner DN. 2003. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res 20(4):693700.
  • 229
    Fatouros A, Osterberg T, Mikaelsson M. 1997. Recombinant Factor VIII SQ—inactivation kinetics in aqueous solution and the influence of disaccharides and sugar alcohols. Pharm Res 14(6):16791684.
  • 230
    Kudela O, Kontsekova E, Csabayova M, Zahorova K, Kontsek P. 1996. Conformational changes in pH 2 -treated human interferon-alpha2 detected with monoclonal antibodies. Hybridoma 15(3):185189.
  • 231
    Rosenberg AS, Worobec A. 2005. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part III: Effects of manufacturing changes on immunogenicity and the utility of animal immunogenicity studies. BioPharm Int 18(1):3236.
  • 232
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G. 2009. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci doi:10.1002/jps.21989.
  • 233
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):12021205.
  • 234
    Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause H-J, Mahler H-C, Meyer BK, Narhi LO, Nesta DP, Spitznagel T. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci doi:10.1002/jps.22097.
  • 235
    Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14(8):969975.
  • 236
    Parkins DA, Lashmar UT. 2000. The formulation of biopharmaceutical products. Pharm Sci Technol Today 3(4):129137.
  • 237
    Daugherty AL, Mrsny RJ. 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58:686706.
  • 238
    Wang W, Singh SK, Zeng DL, King K, Nema S. 2007. Antibody structure, instability and formulation. J Pharm Sci 96(1):126.
  • 239
    Weiner M, Bernstein IL. 1989. Adverse reactions to drug formulation agents. A handbook of excipients. New York: Marcel Dekker.
  • 240
    Masini E, Planchenault J, Pezziari F, Gautier P, Gagnol JP. 1985. Histamine-releasing properties of polysorbate 80 in vitro and in vivo. Correlation with its hypotensive properties in dogs. Agents Actions 16(6):470477.
  • 241
    Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M. 1988. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 9:142148.
  • 242
    Coors EA, Seybold H, Merk HF, Mahler V. 2005. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 95:593599.
  • 243
    Price KS, Hamilton RG. 2007. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28:313319.
  • 244
    ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. 2003. Pharmacological effects of formulation vehicles. Implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665685.
  • 245
    Kerwin BA. 2008. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci 97(8):29242935.
  • 246
    Mueller R, Karle A, Vogt A, Kropshofer H, Ross A, Maeder K, Mahler H-C. 2009. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci 98(10):35483561.
  • 247
    Ha E, Wang W, Wang JY. 2002. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91(10):22522264.
  • 248
    Wang W, Wang YJ, Wang DQ. 2008. Dual effects of Tween 80 on protein stability. Int J Pharm 347(1–2):3138.
  • 249
    Hermeling S, Schellekens H, Crommelin DJA, Jiskoot W. 2003. Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm Res 20(12):19031907.
  • 250
    Hermeling S, Jiskoot W, Crommelin DJA, Schellekens H. 2006. Reaction to the paper: Interaction of polysorbate 80 with erythropoietin: A case study in protein–surfactant interactions. Pharm Res 23(3):641642.
  • 251
    Villalobos AP, Gunturi SR, Heavner GA. 2005. Interaction of polysorbate 80 with erythropoietin: A case study in protein–surfactant interactions. Pharm Res 22:11861194.
  • 252
    European Medicines Agency. 2007. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency, Doc. Ref. EMEA/CHMP/BMWP/14327/2006.
  • 253
    Anonymus. 1999. Renal insufficiency and failure associated with immune globulin intravenous therapy—United States, 1985–1998. MMWR Morb Mortal Wkly Rep 48(24):518521.
  • 254
    Winward DB, Brophy MT. 1995. Acute renal failure after administration of intravenous immunoglobulin: Review of the literature and case report. Pharmacotherapy 15(6):765772.
  • 255
    Martin TD. 2006. IGIV: Contents, properties, and methods of industrial production—evolving closer to a more physiologic product. Int Immunopharmacol 6:517522.
  • 256
    McCue JP, Hein RH, Tenold R. 1986. Three generations of immunoglobulin g preparations for clinical use. Rev Infect Dis 8(Suppl. 4):S374S381.
  • 257
    Shah S. 2005. Pharmacy considerations for the use of IGIV therapy. Am J Health-Syst Pharm 62(Suppl. 3):S5S11.
  • 258
    Anonymus. 2001. Fructose and sorbitol containing parenteral solutions should not be used. Curr Prob Pharmacovigilance 27:13.
  • 259
    Banks DD, Hambly DM, Scavezze JL, Siska CC, Stackhouse NL, Gadgil HS. 2009. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci doi:10.1002/jps.21749.
  • 260
    Gadgil HS, Bondarenko PV, Pipes G, Rehder D, Mcauley A, Perico N, Dillon T, Ricci M, Treuheit M. 2007. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96(10):26072621.
  • 261
    O'Brien J. 1996. Stability of trehalose, sucrose and glucose to nonenzymatic browning in model systems. J Food Sci 61(4):679682.
  • 262
    Roser B. 1991. Trehalose. A new approach to premium dried foods. Trends Food Sci Technol 2:166169.
  • 263
    Bayer HealthCare Pharmaceuticals. 2008. Leukine: Market withdrawal and replacement program for liquid leukine. Letter to U.S. health care professional. 23 January 2008. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm090918.htm. Accessed January 2009.
  • 264
    Food and Drug Administration.2005. Guidance for industry. Nonclinical studies for the safety evaluation of pharmaceutical excipients. Rockville, MD: Food and Drug Administration.
  • 265
    Osterberg RE, See NA. 2003. Toxicity of excipients—a food and drug administration perspective. Int J Toxicol 22:377380.
  • 266
    Food and Drug Administration.1999. Guidance for industry. Container closure systems for packaging human drug and biologics. Rockville, MD: Food and Drug Administration.
  • 267
    Casadevall N. 2002. Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 17(Suppl. 5):4247.
  • 268
    Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469475.
  • 269
    Eckardt K-U, Casadevall N. 2003. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18:865869.
  • 270
    Macdougall IC. 2004. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 20(1):8386.
  • 271
    Schellekens H. 2005. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Practice Res Clin Haematol 18(3):473480.
  • 272
    Smalling R, Foote MA, Molineux G, Swanson SJ, Elliott S. 2004. Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge. Biotechnol Annu Rev 10:237250.
  • 273
    Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. 2005. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67:23462353.
  • 274
    Sharma B, Bader F, Templeman T, Lisi P, Ryan M, Heavner GA. 2004. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Eur J Hosp Pharm 5:8691.
  • 275
    Schellekens H, Jiskoot W. 2006. Erythropoietin-associated PRCA: Still an unsolved mystery. J Immunotoxicol 3:123130.
  • 276
    Haselbeck A. 2003. Epoetins: Differences and their relevance to immunogenicity. Curr Med Res Opin 19(5):430432.
  • 277
    Primeau M-N, Adkinson F, Hamilton RG. 2001. Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions. J Allergy Clin Immunol 107:958962.
  • 278
    Poland GA, Ovsyanikova IG, Jones RT, Yunginger JW. 2004. Latex allergens are not detectable in reconstituted smallpox vaccine or vaccine vial stoppers. J Allergy Clin Immunol 114(2):454456.
  • 279
    Rusyn I, Kadiiska MB, Dikalova A, Kono H, Yin M, Tscuchiya K, Mason RP, Peters JM, Gonzalez J, Segal BH, Holland SM, Thurman RG. 2001. Phthalates rapidly increase production of reactive oxygen species in vivo: Role of Kupffer cells. Mol Pharmacol 59(4):744750.
  • 280
    Hanawa T, Muramatsu E, Asakawa K, Suzuki M, Tanaka M, Kawano K, Seki T, Juni K, Nakajima S. 2000. Investigation of the release behavior of diethylhexylphthalate from the polyvinyl-chloride tubing for intravenous injection. Int J Pharm 210:109115.
  • 281
    Larsen ST, Lund RM, Nielsen GD, Thygesen P, Poulson OM. 2001. Di-(2-ethylhexyl)phthalate possess an adjuvant effect in a subcutaneous injection model with BALB/c mice. Toxicol Lett 125:1118.
  • 282
    Larsen ST, Lund RM, Nielsen GD, Thygesen P, Poulson OM. 2002. Adjuvant effect of di-n-butyl, di-n-octyl, di-iso-nonyl, and di-iso-decyl phthalate in a subcutaneous injection model with BALB/c mice. Pharmacol Toxicol 91:264272.
  • 283
    Wyeth. 2008. Xyntha(rhFactorVIII). Full prescribing information from Wyeth. Philadelphia, PA, USA. http://www.xyntha.com/. Accessed January 2009
  • 284
    Chantelau EA, Berger M, Bohlken B. 1986. Silicone oil released from disposable insulin syringes. Diabetes Care 9(6):672673.
  • 285
    Bernstein RK. 1987. Clouding and deactivation of clear (regular) human insulin: Association with silicone oil from disposable syringes. Diabetes Care 10(6):786787.
  • 286
    PDA 1988. Siliconization of parenteral drug packaging components (Technical Report No. 12). J Parenteral Sci Tech 42(4S):S1S13.
  • 287
    Naim JO, Ippolito KML, van Oss CJ. 1997. Adjuvancy effect of different types of silicone gel. J Biomed Mater Res 37:534538.
  • 288
    Pan G, Goldstein J, Rivera J, Tracy S, Agarkhed M, Pirrotta D, Srivastava A, Tarnowski J. 2006. A study of the effect of silicone oil coatings in syringes on monoclonal antibody aggregation. In National Biotechnology Conference. Boston: AAPS, Poster M1050.
  • 289
    Bristol-Myers Squibb Company. 2007. Orencia (abatacept). Full prescribing information from Bristol-Myers Squibb Company. New York, NY, USA. http://www.orencia.com. Accessed February 2009.
  • 290
    Baumann A. 2009. Foundation review: Nonclinical development of biopharmaceuticals. Drug Discov Today 14(23–24):11121122.
  • 291
    Cavagnaro JA. 2002. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev: Drug Discov 1:469475.
  • 292
    Chapman K, Pullen N, Graham M, Ragan I. 2007. Preclinical safety testing of monoclonal antibodies: The significance of species relevance. Nat Rev Drug Discov 6:120126.
  • 293
    Bugelski PJ, Treacy G. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6(1):1016.
  • 294
    Wierda D, Smith HW, Zwickl CM. 2001. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158:7174.
  • 295
    Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2007. Immunogenicity of therapeutic proteins. In Handbook of pharmaceutical biotechnology; GadSC, Ed. New York: John Wiley & Sons, Inc., pp. 815833.
  • 296
    De Groot AS, Moise L. 2007. Prediction of immunogenicity for therapeutic proteins: State of the art. Curr Opin Drug Disc Dev 10(3):332340.
  • 297
    Perry LCA, Jones TD, Baker MP. 2008. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R&D 9(6):385396.
  • 298
    Reipert BM, Steinitz KN, van Helden PM, Unterthurner S, Schuster M, Ahmad RU, Ilas J, Schwarz HP. 2009. Opportunities and limitations of mouse models humanized for HLA Class II antigens. J Throm Haemost 7(Suppl. 1):9297.
  • 299
    Wurm FL. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):13931398.
  • 300
    Glynn J, Hagerty T, Pabst T, Annanthur G, Thomas K, Johnson P, Ramasubramanyan N, Mensah P. 2009. The development and application of a monoclonal antibody purification platform. BioPharm Int 22(3, Suppl.):1620.
  • 301
    Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B 848:2839.
  • 302
    Singh SK, Rathore N, McAuley A, Rathore AS. 2009. Best Practices for formulation and manufacturing of biotech drug products. BioPharm Int 22(6):3248.
  • 303
    Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 106(29):1193711942.
  • 304
    Filikov AV, Hayes RJ, Luo P, Stark DM, Chan C, Kundu A, Dahiyat BI. 2002. Computational stabilization of human growth hormone. Prot Sci 11:14521461.
  • 305
    Kumar S, Singh SK, Gromiha MM. 2010. Temperature dependent molecular adaptations in microbial proteins: Lessons for structure based biologic drug design and development. In Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology; FlickingerMC, DrewSW, SpierRE, Eds. New York: John Wiley & Sons, Inc., pp. 46474661.
  • 306
    Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. 2007. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:2632.
  • 307
    Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies. Residual immunogenicity resides in the CDR regions. mAbs 2(3):110.
  • 308
    Wang X, Singh SK, Kumar S. 2010. Potential aggregation prone regions in complementarity determining regions of antibodies and their contribution towards antigen recognition. Pharm Res doi:10.1007/s11095-010-0143-5.
  • 309
    Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. 2008. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300(16):18871896.